Company Website:
http://www.oxybiomed.com
MORRISVILLE, N.C. -- (Business Wire)
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical
company focused on developing and commercializing a portfolio of
products for the critical care market, announced today that the Company
will host a conference call and live audio webcast on Tuesday, July 29,
2014, at 8:30 a.m. ET to report financial results for the fourth quarter
and fiscal year ended April 30, 2014, and provide a corporate update.
To participate in the call, please dial 877‐407‐8029 (domestic) or
201‐689‐8029 (international) and refer to conference ID 13585285. A live
webcast of the call can be accessed under “Events and Presentations” in
the Investors section of the Company’s website at www.oxybiomed.com.
An archived webcast recording will be available on the Oxygen
Biotherapeutics website beginning approximately two hours after the call.
About Oxygen Biotherapeutics
Oxygen Biotherapeutics, Inc. is a specialty pharmaceutical company
focused on developing and commercializing a portfolio of products for
the critical care market. The company recently acquired the North
American rights to develop and commercialize levosimendan, and the
United States Food and Drug Administration (FDA) has granted Fast Track
status for levosimendan for the reduction of morbidity and mortality in
cardiac surgery patients at risk for developing Low Cardiac Output
Syndrome (LCOS). The company plans to start a Phase 3 trial with
levosimendan in that indication during the third quarter of 2014, and
has also developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier called Oxycyte® that is currently in clinical
and preclinical studies for intravenous delivery for indications such as
traumatic brain injury, decompression sickness and stroke.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the
company that involve risks and uncertainties and reflect the company’s
judgment as of the date of this release. The forward-looking statements
are subject to a number of risks and uncertainties, including, matters
beyond the company's control that could lead to delays in the clinical
study, delays in new product introductions and customer acceptance of
these new products, and other risks and uncertainties as described in
the company’s filings with the Securities and Exchange Commission,
including in its quarterly report on Form 10-Q filed on March 17, 2014,
and annual report on Form 10-K filed on June 26, 2013, as well as its
other filings with the SEC. The company disclaims any intent or
obligation to update these forward-looking statements beyond the date of
this release. Statements in this press release regarding management’s
future expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995.
Contacts:
Stern Investor Relations
Jesse Baumgartner, 212-362-1200
jesse@sternir.com
Source: Oxygen Biotherapeutics, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.